These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3896288)

  • 1. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
    MacLennan IC; Cusick J
    Br J Cancer; 1985 Aug; 52(2):153-8. PubMed ID: 3896288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
    MacLennan IC; Chapman C; Dunn J; Kelly K
    Lancet; 1992 Jan; 339(8787):200-5. PubMed ID: 1346171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):823-30. PubMed ID: 7006664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):813-22. PubMed ID: 7006663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.
    Crowley J; Jacobson J; Alexanian R
    Semin Hematol; 2001 Jul; 38(3):203-8. PubMed ID: 11486307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results and further perspectives of plasmocytoma chemotherapy.
    Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
    Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Coleman M; Cooper MR; Henderson E
    J Clin Oncol; 1988 Sep; 6(9):1481-90. PubMed ID: 3047338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
    Belch A; Shelley W; Bergsagel D; Wilson K; Klimo P; White D; Willan A
    Br J Cancer; 1988 Jan; 57(1):94-9. PubMed ID: 3279997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
    Johnsen HE; Bergmann OJ; Boesen AM; Pedersen BB; Ellegaard J; Bastrup-Madsen P
    Ugeskr Laeger; 1989 Mar; 151(13):816-21. PubMed ID: 2718264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.
    Cuzick J; Erskine S; Edelman D; Galton DA
    Br J Cancer; 1987 May; 55(5):523-9. PubMed ID: 3300761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
    Pavlovsky S; Corrado C; Santarelli MT; Saslavsky J; Cavagnaro F; Palau M; de Tezanos Pinto M; Huberman A; Lein JM
    J Clin Oncol; 1988 May; 6(5):769-75. PubMed ID: 3284974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic index for multiple myeloma.
    Grignani G; Gobbi PG; Formisano R; Pieresca C; Ucci G; Brugnatelli S; Riccardi A; Ascari E
    Br J Cancer; 1996 May; 73(9):1101-7. PubMed ID: 8624271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.
    Salmon SE; Haut A; Bonnet JD; Amare M; Weick JK; Durie BG; Dixon DO
    J Clin Oncol; 1983 Aug; 1(8):453-61. PubMed ID: 6366141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.